[1]黄宝亮,黄晓燕,黄文森,等.新型脂肪因子FAM19A5在代谢性疾病中的研究进展[J].国际内分泌代谢杂志,2024,44(01):19-22.[doi:10.3760/cma.j.cn121383-20230220-02039]
　Huang Baoliang,Huang Xiaoyan,Huang Wensen,et al.Research progress of novel adipokine FAM19A5 in metabolic diseases[J].International Journal of Endocrinology and Metabolism,2024,44(01):19-22.[doi:10.3760/cma.j.cn121383-20230220-02039]
点击复制

新型脂肪因子FAM19A5在代谢性疾病中的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
44
期数:
2024年01期
页码:
19-22
栏目:
综述
出版日期:
2024-01-20

文章信息/Info

Title:
Research progress of novel adipokine FAM19A5 in metabolic diseases
作者:
黄宝亮; 黄晓燕; 黄文森; 张翼
福建医科大学附属泉州第一医院内分泌科,泉州 362000
Author(s):
Huang Baoliang;  Huang Xiaoyan;  Huang Wensen;  Zhang Yi
Department of Endocrinology, First Hospital of Quanzhou Affiliated to Fujian Medical university, Quanzhou 362000, China
关键词:
序列相似家族19成员A5;  脂肪因子;  代谢性疾病
Keywords:
Family with Sequence Similarity 19;  Member A5;  adipokine;  Metabolic diseases
DOI:
10.3760/cma.j.cn121383-20230220-02039
摘要:
序列相似家族19成员A5(family with sequence similarity 19, member A5,FAM19A5)是近年来新发现的脂肪因子。研究发现,FAM19A5与肥胖、胰岛素抵抗、非酒精性脂肪肝病等代谢性疾病密切相关,这表明FAM19A5有希望成为新型代谢性疾病生物标记物。本文对FAM19A5与代谢性疾病的相关性及可能的作用机制进行归纳综述,以期为FAM19A5的相关研究提供线索。
Abstract:
Family with sequence similarity 19, member A5(FAM19A5)is a newly discovered adipokine in recent years. It has been found that FAM19A5 is closely associated with metabolic diseases such as obesity, insulin resistance, and non-alcoholic fatty liver disease, which suggests that FAM19A5 is promising as a novel metabolic disease biomarker. In this paper, we summarize and review the correlation between FAM19A5 and metabolic diseases and the possible mechanisms of action, in order to provide clues for the related research of FAM19A5.

参考文献/References:

[1] Frohlich J,Chaldakov GN,Vinciguerra M.Cardio-and neurometabolic adipobiology:consequences and implications for therapy[J].Int J Mol Sci,2021,22(8):4137.DOI:10.3390/ijms22084137.
[2] Recinella L,Orlando G,Ferrante C,et al.Adipokines:new potential therapeutic target for obesity and metabolic,rheumatic,and cardiovascular diseases[J].Front Physiol,2020,11:578966.DOI:10.3389/fphys.2020.578966.
[3] 张娴,陈宏.新型脂肪因子与肥胖相关代谢性疾病[J].国际内分泌代谢杂志,2018,38(3):171-175.DOI:10.3760/cma.j.issn.1673-4157.2018.03.007.
[4] Wang Y,Chen D,Zhang Y,et al.Novel adipokine,FAM19A5,inhibits neointima formation after injury through sphingosine-1-phosphate receptor 2[J].Circulation,2018,138(1):48-63.DOI:10.1161/CIRCULATIONAHA.117.032398.
[5] Park MY,Kim HS,Lee M,et al.FAM19A5,a brain-specific chemokine,inhibits rankl-induced osteoclast formation through formyl peptide receptor 2[J].Sci Rep,2017,7(1):15575.DOI:10.1038/s41598-017-15586-0.
[6] Tom Tang Y,Emtage P,Funk WD,et al.Tafa:a novel secreted family with conserved cysteine residues and restricted expression in the brain[J].Genomics,2004,83(4):727-734.DOI:10.1016/j.ygeno.2003.10.006.
[7] Yari FA,Shabani P,Karami S,et al.Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease[J].BMC Endocr Disord,2021,21(1):153.DOI:10.1186/s12902-021-00820-8.
[8] Sarver DC,Lei X,Wong GW.Fam19a(tafa):an emerging family of neurokines with diverse functions in the central and peripheral nervous system[J].ACS Chem Neurosci,2021,12(6):945-958.DOI:10.1021/acschemneuro.0c00757.
[9] Li J,Li S,Song Y,et al.Association of serum FAM19A5 with cognitive impairment in vascular dementia[J].Dis Markers,2020,2020:e8895900.DOI:10.1155/2020/8895900.
[10] Lee YB,Hwang HJ,Kim JA,et al.Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes[J].Diab Vasc Dis Res,2019,16(6):530-538.DOI:10.1177/1479164119860746.
[11] Unamuno X,Gómez-Ambrosi J,Rodríguez A,et al.Adipokine dysregulation and adipose tissue inflammation in human obesity[J].Eur J Clin Invest,2018,48(9):e12997.DOI:10.1111/eci.12997.
[12] Xie K,Liu L,Yin C,et al.Follistatin-like 1 and family with sequence similarity to 19 member a5 levels are decreased in obese children and associated with glucose metabolism[J].Ann Nutr Metab,2022,78(4):213-221.DOI:10.1159/000524624.
[13] Wesolek A,Skoracka K,Skrypnik K,et al.Assessment of progranulin and FAM19A5 protein blood levels in patients with metabolic syndrome[J].J Physiol Pharmacol,2022,73(1).DOI:10.26402/jpp.2022.1.13.
[14] Lee S,Karvonen-Gutierrez C,Mukherjee B,et al.Race-specific associations of urinary phenols and parabens with adipokines in midlife women:the study of women's health across the nation(swan)[J].Environ Pollut,2022,303:119164.DOI:10.1016/j.envpol.2022.119164.
[15] Kitada Y,Kajita K,Taguchi K,et al.Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates high-fat diet-induced adipocyte hypertrophy and systemic glucose intolerance in mice[J].Endocrinology,2016,157(5):1839-1851.DOI:10.1210/en.2015-1768.
[16] Lee SH,Park SY,Choi CS.Insulin resistance:from mechanisms to therapeutic strategies[J].Diabetes Metab J,2022,46(1):15-37.DOI:10.4093/dmj.2021.0280.
[17] Li Y,Ding L,Hassan W,et al.Adipokines and hepatic insulin resistance[J].J Diabetes Res,2013,2013:170532.DOI:10.1155/2013/170532.
[18] 张梓涵,杨丽霞,贺云.脂肪因子、炎症因子与胰岛素抵抗分子机制研究进展[J].中医临床研究,2021,13(28):144-148.DOI:10.3969/j.issn.1674-7860.2021.28.045.
[19] Yoon JH,Kim D,Jang JH,et al.Proteomic analysis of the palmitate-induced myotube secretome reveals involvement of the annexin a1-formyl peptide receptor 2(fpr2)pathway in insulin resistance[J].Mol Cell Proteomics,2015,14(4):882-892.DOI:10.1074/mcp.M114.039651.
[20] Kolb H,Kempf K,Röhling M,et al.Insulin:too much of a good thing is bad[J].BMC Med,2020,18(1):224.DOI:10.1186/s12916-020-01688-6.
[21] Purvis GSD,Collino M,Loiola RA,et al.Identification of annexina1 as an endogenous regulator of rhoa,and its role in the pathophysiology and experimental therapy of type-2 diabetes[J].Front Immunol,2019,10:571.DOI:10.3389/fimmu.2019.00571.
[22] Czaja MJ.Function of autophagy in nonalcoholic fatty liver disease[J].Dig Dis Sci,2016,61(5):1304-1313.DOI:10.1007/s10620-015-4025-x.
[23] Álvarez-Mercado AI,Rojano-Alfonso C,Micó-Carnero M,et al.New insights into the role of autophagy in liver surgery in the setting of metabolic syndrome and related diseases[J].Front Cell Dev Biol,2021,9:670273.DOI:10.3389/fcell.2021.670273.
[24] Kwong E,Li Y,Hylemon PB,et al.Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism[J].Acta Pharm Sin B,2015,5(2):151-157.DOI:10.1016/j.apsb.2014.12.009.
[25] Karlstaedt A,Moslehi J,De Boer RA.Cardio-onco-metabolism:metabolic remodelling in cardiovascular disease and cancer[J].Nature Reviews Cardiology,2022,19(6):414-425.DOI:10.1038/s41569-022-00698-6.
[26] Ma F,Hao J,Zhao J,et al.Circulating FAM19A5 level is associated with the presence and severity of coronary artery disease[J].Int J Cardiol,2022,354:50-55.DOI:10.1016/j.ijcard.2022.03.011.

相似文献/References:

[1]郑辉,葛焕琦.网膜素对心血管系统的影响[J].国际内分泌代谢杂志,2016,36(04):261.[doi:10.3760/cma.j.issn.1673-4157.2016.04.12]
　Zheng Hui,Ge Huanqi.Effects of omentin on cardiovascular system[J].International Journal of Endocrinology and Metabolism,2016,36(01):261.[doi:10.3760/cma.j.issn.1673-4157.2016.04.12]
[2]田清武,孙树凯,翟玉娥,等.雌激素对去卵巢大鼠内脏脂肪细胞脂肪因子表达水平的影响[J].国际内分泌代谢杂志,2016,36(06):374.[doi:10.3760/cma.j.issn.1673-4157.2016.06.04]
　Tian Qingwu*,Sun Shukai,Zhai Yue,et al.Effects of estrogen on the expression of adipokines in visceral fat cells in ovariectomized rats[J].International Journal of Endocrinology and Metabolism,2016,36(01):374.[doi:10.3760/cma.j.issn.1673-4157.2016.06.04]
[3]张娴 陈宏.新型脂肪因子与肥胖相关代谢性疾病[J].国际内分泌代谢杂志,2018,38(03):171.[doi:10.3760/cma.j.issn.1673-4157.2018.03.007]
　Zhang Xian,Chen Hong.Novel adipokines and obesity-related metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(01):171.[doi:10.3760/cma.j.issn.1673-4157.2018.03.007]

备注/Memo

备注/Memo:
基金项目:泉州市科技计划项目(2022NS066)
通信作者:张翼,Email:zhayisn@163.com
更新日期/Last Update: 2024-03-20